Morgan Stanley Remains a Hold on Ascendis Pharma (ASND)
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a ...
Seeking Alpha12d
ASND Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The ...
Nasdaq2mon
Ascendis Pharma's sBLA for TransCon hGH in Adult Growth Hormone Deficiency Accepted by FDA for Review
except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA ...
Yahoo Finance28d
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.) The legal action, which would result in a decision in the next 12-15 months, is based on BioMarin's belief that Ascendis ...
Business Insider1mon
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare ...
Morningstar29d
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones.